Tipranavir: A Ritonavir-Boosted Protease Inhibitor: A Viewpoint by Charles Hicks

By Hicks Charles  

Drugs, Vol. 65, Iss. 12, 2005-01 ,pp. : 1678-1679

Adis International

Access to resources Recommend Favorite

Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline

By  

Reactions Weekly, Vol. 1, Iss. 1188, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Comparison of the Pharmacokinetics of Apricitabine in the Presence and Absence of Ritonavir-Boosted Tipranavir: A Phase I, Open-Label, Controlled, Single-Centre Study

By Cox Susan  

Clinical Drug Investigation, Vol. 29, Iss. 11, 2009-11 ,pp. : 721-728

Adis International

Access to resources Recommend Favorite

Tipranavir: A Novel Nonpeptidic Protease Inhibitor of HIV

By King Jennifer R.   Acosta Edward P.  

Clinical Pharmacokinetics, Vol. 45, Iss. 7, 2006-01 ,pp. : 665-682

Adis International

Access to resources Recommend Favorite